A case-case-control investigation (N = 255 patients) explored the epidemiology of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Recent exposure to carbapenems and a rapidly fatal condition should prompt practitioners to shorten delays in initiating appropriate therapy, which can adversely impact CRPA outcomes, as opposed to the isolated impact of the carbapenem resistance determinant.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/ice.2018.181 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!